Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 447 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR What to Know About Cancer Clinical Trial Matching Programs March 14, 2023 Radio Hosts Test Sanity For Charity By Listening to ‘Baby Shark’... November 20, 2019 Active Surveillance for Low-Risk Prostate Cancer Continues to Rise June 23, 2022 ASCO Annual Meeting 2023: Adding Durvalumab and Olaparib to Treatment Delays... June 3, 2023 Load more HOT NEWS Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic... Veteran Avoided The Barber For 6 Years After He Left The... Research with integrity – why colour blindness is a research integrity... High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast...
